Expectations trend
FY2028 · fiscal year ending 2028-01-31 · fmp
Nutriband Inc (NTRB)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$5.58-8.31%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
3.66 → 3.66 EPS · FY ending Jan 31, 2028 · 1 analyst
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
Change in the same fiscal period’s mean EPS estimate from Oct 6, 2026 to Nov 5, 2026: (new ÷ prior − 1). Contributor count changed from 1 to 1; this is not the number of analysts revising. The ±10% axis is a display range.
The EPS and P/E reference is not available for NTRB yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Maintain liquidity with $5M credit line at 7% interest | The company secured a $5M credit line to support growth. | Intact | credit line is reduced or withdrawn before 2027-Q1 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of last 2 quarters. Operating income remains negative, -$1.25M in 2027-Q1 and -$0.89M in 2027-Q2, with net losses continuing. The credit line provides stable financing without equity dilution. Management maintains financial discipline but losses persist, indicating mixed progress. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-01-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Dec 9, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, early-stage commercial story rather than an established earnings compounder. The long-term thesis is intact this month, with recent financial performance still in the top half of its industry, but the business remains loss-making.
The valuation is expensive versus peers, while the evidence points to optionality as the main source of disagreement about expectations. The priced-in signal is labeled unjustified, but its fragility tier is low because the snapshot identifies expensive valuation alone, not a combination of expensive, weak, and turbulent conditions.
Over the near term, continued execution on reducing losses is supported by operating income and net losses narrowing through 2027-Q2, though both remain negative. Commercial progress on the fentanyl patch is still limited: revenue declined from 2026-Q2 to 2027-Q2 despite management’s continued focus, and a guidance cut on the next call is a stated risk.
The multi-year thesis depends on further loss reduction and whether the fentanyl patch gains commercial traction. Near-term conditions also matter: weaker jobs data could weigh on cyclical healthcare names, while continued earnings strength and higher guidance from sector bellwethers could support sector momentum.
The 1-3 year view is mixed: improving losses and an FDA approval are constructive, but persistent losses, limited product revenue progress, and an expensive peer valuation keep execution risk high. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Reduce operating losses and net income deficits | Operating losses have improved from -$3.88M to -$1.25M recently. | Intact | operating losses worsen beyond -$1.25M by 2027-Q1 | Operating income: $-890,637 FY2027-Q2; GAAP. Published target: operating income improves to at least -$1.25M. The stored target says 2027-Q1; this source reports FY2027-Q2. Fiscal/calendar alignment needs review. Sep 4, 2026-890,637 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 5 of last 5 quarters. Operating income improved significantly from -$3.88M in 2026-Q3 to -$0.89M in 2027-Q2; net losses also narrowed from -$3.87M to -$0.88M. Management has consistently emphasized reducing losses and the financials show delivering progress on this priority. Delivery assessment Sep 20, 2026 |
Commercialize abuse deterrent fentanyl transdermal system | A primary condition in Nutriband Inc's published investment case. The stated target is reach $80M to $200M peak annual US sales. | Intact | annual US sales fail to grow toward $80M by 2026-Q1 | Revenue: $437,514 FY2027-Q2; GAAP. Published target: reach $80M to $200M peak annual US sales. The stored target says 2026-Q1; this source reports FY2027-Q2. Fiscal/calendar alignment needs review. Sep 4, 2026437,514 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated as a priority in 3 of last 3 quarters. Revenue declined from $622K in 2026-Q2 to $438K in 2027-Q2, reflecting early commercial stage. Management projects peak US sales of $80M to $200M annually for the fentanyl patch. The trajectory shows limited revenue progress so far but consistent focus on commercialization. Delivery assessment Sep 20, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$3.66 → $3.66 · observed estimates
$0.18B → $0.18B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-07-25 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-07-26 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-07-27 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-07-28 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-07-29 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-07-30 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-07-31 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-08-01 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-08-02 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-08-03 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-08-04 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-08-05 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-08-06 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-08-07 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-08-08 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-08-09 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-08-10 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-08-12 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-08-13 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-08-14 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-08-15 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-08-16 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-08-17 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-08-18 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-08-19 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-08-20 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-08-21 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-08-22 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-08-23 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-08-24 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-08-25 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-08-26 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-08-27 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-08-28 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-08-29 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-08-30 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-08-31 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-09-01 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-09-02 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-09-03 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-09-04 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-09-05 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-09-06 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-09-07 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-09-08 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-09-09 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-09-10 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-09-11 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-09-12 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-09-13 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-09-14 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-09-15 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-09-16 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-09-17 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-09-18 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-09-19 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-09-20 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-09-21 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-09-22 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-09-23 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-09-24 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-09-25 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-09-26 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-09-27 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-09-28 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-09-29 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-09-30 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-10-01 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-10-02 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-10-03 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-10-04 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-10-05 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-10-06 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-10-07 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-10-08 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-10-09 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-10-10 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-10-11 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-10-12 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-10-13 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-10-14 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-10-15 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-10-16 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-10-17 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-10-18 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-10-19 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-10-20 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-10-21 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-10-22 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-10-23 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-10-24 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-10-25 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-10-26 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-10-27 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-10-28 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-10-29 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-10-30 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-10-31 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-11-01 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-11-02 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-11-03 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-11-04 | $3.66 | $180,410,000 | 1 / 1 |
| 2026-11-05 | $3.66 | $180,410,000 | 1 / 1 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 1 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.